Canada markets closed

InnoCan Pharma Corporation (INNO.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.3100+0.0050 (+1.64%)
At close: 03:20PM EST

InnoCan Pharma Corporation

1015, 926 – 5 Avenue SW
Calgary, AB T2P 0N7

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Ron MayronExecutive Chairman210.33kN/A1963
Ms. Iris BincovichCEO & Director540.65kN/A1969
Mr. Yoram DruckerFounder & Executive VP of Business Development233.25kN/A1965
Mr. Nelson Harvey Halpern F.C.A., FCPAChief Financial Officer98.42kN/A1959
Roni KamhiCOO & CEO of BI Sky GlobalN/AN/AN/A
Mr. Eyal Flom L.L.M., M.B.A.Director & Company SecretaryN/AN/A1966
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. It engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes to pain relief and treatment of epilepsy and other central nervous system disorders and other indications. The company offers its products under the Shir and Relief & Go brand names. It is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The company was incorporated in 2018 and is headquartered in Calgary, Canada.

Corporate Governance

InnoCan Pharma Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.